Remus Pharmaceuticals H1FY26 Concall Decoded: “When 47 Crores Feels Like 400 — The Global Hustle of a Pharma Nomad”
1. Opening Hook
Remember when Indian pharma companies were called “copycats”? Remus is out here proving they’re the export hustlers. The company doesn’t even bother making drugs in-house — they just own the IPs, brands, and global distributors like it’s a chess game. With a footprint in 40 countries and ambitions in every continent that still uses paracetamol, MD Arpit Shah sounds more like a travel blogger than a pharma exec. Latin America calls him “Señor Generics,” and Africa’s next on his map.
By the time you reach the B2C vs B2B saga, you’ll wonder if Remus is building a pharma empire or just outsmarting the global supply chain — read on, it gets spicy.
2. At a Glance
Revenue up 47% (₹400 Cr): CFO insists it’s growth, not arithmetic error.
EBITDA +28% (₹27 Cr): Still smaller than MD’s air miles.
Margins at 6.75%: Because 80% comes from a low-margin U.S. unit — capitalism strikes again.
PAT +21% (₹22 Cr): Profit grew, but so did the CFO’s Excel tabs.
Standalone Revenue ₹47 Cr (+24%): The domestic child outperformed its global parent.
PAT Margin 25.6% standalone: Proof that “small but desi” still wins in pharma math.
3. Management’s Key Commentary
“Our formulations reach over 40 countries.” (Translation: The sun never sets on Remus’ invoice trail. 😏)
“95% of exports are advanced and niche formulations.” (Translation: We sell fancy pills in fancy packaging.)
“B2C business grew from 4% to 13% this half.” (Translation: We finally realized consumers pay better than distributors.)
“We don’t do African tenders — margins there are a myth.” (Translation: Let others race to the bottom; we’ll sip lattes in Latin America.)
“We expect PAT margin to rise from 5% to 8-10%.” (Translation: Assuming Excel, gods, and global inflation align.)
“We’re light asset — we don’t manufacture, we brand.” (Translation: No factories, no headaches — just invoices and IPs.)
“MD travels 180 days a year to inspect markets.” (Translation: He’s literally the traveling salesman of pharma. ✈️)
4. Numbers Decoded
Metric
H1FY26
YoY Growth
Commentary
Revenue (Consolidated)
₹400 Cr
+47%
Mostly powered by U.S. subsidiary (80% of total).
EBITDA
₹27 Cr
+28%
Margins 6.75%; dragged by volume-heavy U.S. ops.
PAT
₹22 Cr
+21%
Margins 5.4%; CFO promises better blend ahead.
Standalone Revenue
₹47 Cr
+24%
India ops growing faster, higher profitability.
Standalone PAT
₹12 Cr
+31%
PAT margin 25.6% – now that’s real medicine.
B2C Share
13%
vs 4% YoY
Aim: 20-25% in next 18 months.
EBITDA Margin (B2B vs B2C)
32-33% vs 35%+
—
Proof that brands make fatter margins than bulk orders.
👉 The U.S. Espee subsidiary is a high-volume, low-EBITDA play — the culprit behind blended margins. But management claims they’ve already recovered 90% of the acquisition cost. Pharma math never fails to surprise.
5. Analyst Questions
Q: Why chase Africa if local players have cost advantages? A: “We prefer 20% of a premium market over 80% of penny tenders.” (Translation: Pride over price.)
Q: How confident are you in margin expansion without factories? A: “We have IPs, brands, and trademarks — who needs machines?” (Translation: Paper > Plant.)
Q: What’s the growth outlook for B2C? A: “From 13% to 25% in 1.5 years.” (Translation: Pray for regulators and customs clearance.)
Q: Why are margins low despite B2C? A: “Because 80% revenue comes from our U.S. subsidiary.” (Translation: We make money in rupees, report in dollars. 💸)
6. Guidance & Outlook
Management expects PAT margins to climb to 8–10%, powered by an increasing B2C mix and expansion in Latin America and Africa (private markets only — no penny tenders). The
